Zacks Research Weighs in on Humana’s Q1 Earnings (NYSE:HUM)

Humana Inc. (NYSE:HUM) – Research analysts at Zacks Research boosted their Q1 2025 EPS estimates for Humana in a note issued to investors on Tuesday, February 25th. Zacks Research analyst D. Chatterjee now forecasts that the insurance provider will post earnings per share of $9.91 for the quarter, up from their previous forecast of $6.37. The consensus estimate for Humana’s current full-year earnings is $16.47 per share. Zacks Research also issued estimates for Humana’s Q2 2025 earnings at $5.31 EPS, Q3 2025 earnings at $2.87 EPS, Q4 2025 earnings at ($1.85) EPS, Q2 2026 earnings at $4.29 EPS, Q4 2026 earnings at ($2.41) EPS and FY2026 earnings at $10.92 EPS.

Humana (NYSE:HUM) last released its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%.

A number of other research analysts have also recently weighed in on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $290.00 price objective on shares of Humana in a report on Wednesday, February 12th. Truist Financial lifted their price objective on shares of Humana from $260.00 to $290.00 and gave the company a “hold” rating in a report on Monday, January 6th. Barclays lifted their price objective on shares of Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a report on Thursday, February 13th. JPMorgan Chase & Co. dropped their target price on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 18th. Finally, TD Cowen lifted their target price on shares of Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research report on Monday, November 4th. Nineteen equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $285.68.

Humana Stock Up 3.6 %

HUM opened at $270.91 on Friday. Humana has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. The company has a fifty day moving average of $271.11 and a two-hundred day moving average of $287.34. The stock has a market capitalization of $32.68 billion, a price-to-earnings ratio of 27.23, a PEG ratio of 2.05 and a beta of 0.56.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be issued a $0.885 dividend. The ex-dividend date is Friday, March 28th. This represents a $3.54 annualized dividend and a yield of 1.31%. Humana’s payout ratio is 35.58%.

Insider Buying and Selling at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. The trade was a 31.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.32% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Humana

Institutional investors and hedge funds have recently bought and sold shares of the company. Creative Financial Designs Inc. ADV boosted its holdings in Humana by 244.0% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after purchasing an additional 61 shares during the last quarter. Ashton Thomas Securities LLC purchased a new stake in shares of Humana in the 3rd quarter valued at approximately $31,000. FPC Investment Advisory Inc. purchased a new stake in shares of Humana in the 4th quarter valued at approximately $27,000. Centricity Wealth Management LLC purchased a new stake in shares of Humana in the 4th quarter valued at approximately $30,000. Finally, LFA Lugano Financial Advisors SA raised its stake in shares of Humana by 56.3% in the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock valued at $32,000 after acquiring an additional 45 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.